Emerging Pharmaceutical Treatments of Novel COVID-19: A Review.
antimicrobials
antivirals
covid-19
infectious disease
pharmacology
sars-cov-2
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
24 May 2020
24 May 2020
Historique:
entrez:
30
6
2020
pubmed:
1
7
2020
medline:
1
7
2020
Statut:
epublish
Résumé
As a new decade began, COVID-19 quickly gained importance as it became the cause of the current global pandemic. Research has been focusing on studying the structure of SARS-CoV-2 and investigates possible pharmaceutical approaches. With the number of cases increasing every day, globally, multiple drugs are being researched as possible candidates. Although multiple drugs show promise in the treatment of COVID-19 via either inhibiting viral replication or preventing fusion of the virus to the ACE2 receptors, further investigation is still warranted and necessary before the admission of any type of pharmaceutical agent. Furthermore, several supplements have also been documented in being utilized as treatment of COVID-19. The exact mechanism and efficacy of current candidate drugs are still being explored through clinical trials. Despite the advancements in current research with emerging treatments, social distancing and engaging in preventative measures remains crucial to attempt to prevent the occurrence of more cases and deaths, worldwide. This review explores various drugs and their mechanism of action which are either currently being used in clinical trials or may be used in the future for the treatment of COVID-19.
Identifiants
pubmed: 32596078
doi: 10.7759/cureus.8260
pmc: PMC7313429
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e8260Informations de copyright
Copyright © 2020, Hussain et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Ther Clin Risk Manag. 2008 Oct;4(5):1023-33
pubmed: 19209283
Antiviral Res. 2014 Jul;107:84-94
pubmed: 24769245
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
J Med Virol. 2020 Jul;92(7):740-746
pubmed: 32227493
J Infect. 2020 Jul;81(1):e21-e23
pubmed: 32283143
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Science. 2003 Jun 13;300(5626):1763-7
pubmed: 12746549
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443
pubmed: 32307245
J Gen Virol. 1981 Mar;53(Pt 1):93-103
pubmed: 6268743
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105
pubmed: 32284951
Oncologist. 2018 Aug;23(8):943-947
pubmed: 29622697
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
J Hepatobiliary Pancreat Surg. 2006;13(1):42-7
pubmed: 16463210
JAMA. 2020 May 19;323(19):1897-1898
pubmed: 32208486
Nat Rev Rheumatol. 2020 Mar;16(3):155-166
pubmed: 32034323
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
pubmed: 32054787
Drugs. 2003;63(8):769-802
pubmed: 12662125
J Chin Med Assoc. 2020 Jun;83(6):534-536
pubmed: 32243270
J Med Virol. 2020 Jun;92(6):556-563
pubmed: 32104907
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
PLoS Med. 2016 Mar 01;13(3):e1001967
pubmed: 26930627
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Int J Antimicrob Agents. 2020 Apr;55(4):105945
pubmed: 32194152
Turk J Med Sci. 2020 Apr 15;50(SI-1):611-619
pubmed: 32293834
Molecules. 2020 Mar 30;25(7):
pubmed: 32235534
J Phys Chem B. 2010 Jul 1;114(25):8544-54
pubmed: 20527735
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Curr Top Microbiol Immunol. 2005;287:31-55
pubmed: 15609508
Curr Med Chem. 2008;15(10):997-1005
pubmed: 18393857
Travel Med Infect Dis. 2020 Mar - Apr;34:101615
pubmed: 32145386
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Int J Mol Sci. 2020 Apr 10;21(7):
pubmed: 32290293
Int J Antimicrob Agents. 2020 Apr;55(4):105933
pubmed: 32147516
J Med Virol. 2020 May;92(5):479-490
pubmed: 32052466